查看文章

477 EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. REAL-LIFE EVIDENCE FROM ENEIDA REGISTRY. Marisa Iborra, Alejandro Garrido MarÃn, Berta Caballol Oliva, José MarÃa Huguet, Lara Arias GarcÃa, Francisco Mesonero, Samuel J. Ferná ndez-Prada, Marta M. Boscá Watts, à ngel Ponferrada Diaz, Xavier Calvet, Ana Gutié rrez, Ingrid Ordá s, Lucia Ruiz-Sanchez, Beatriz Sicilia, Irene GarcÃa de la Filia, Eugeni DomÃnech, Pilar Nos Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13)(SC-IFX) has been approved for inflammatory bowel disease (IBD). Aim: to evaluate efficacy, safety, pharmacoki-netics and patient experience following a switching to SC-IFX in patients who are in clinical remission on IV-IFX maintenance treatment …